Butylene glycol dicaprate|4196-74-1| biochemical

MedKoo Cat#: 581869 | Name: Butylene glycol dicaprate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Butylene glycol dicaprate is a biochemical.

Chemical Structure

Butylene glycol dicaprate

CAS#4196-74-1

Theoretical Analysis

MedKoo Cat#: 581869

Name: Butylene glycol dicaprate

CAS#: 4196-74-1

Chemical Formula: C24H46O4

Exact Mass: 398.3396

Molecular Weight: 398.63

Elemental Analysis: C, 72.31; H, 11.63; O, 16.05

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Butylene glycol dicaprate; Decanoic acid, 1-methyl-1,3-propanediyl ester; Decanoic acid, 1-methyltrimethylene ester.

IUPAC/Chemical Name

Decanoic acid, 1-methyl-1,3-propanediyl ester

InChi Key

PBFGMXZRJIUGKU-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H46O4/c1-4-6-8-10-12-14-16-18-23(25)27-21-20-22(3)28-24(26)19-17-15-13-11-9-7-5-2/h22H,4-21H2,1-3H3

SMILES Code

CC(OC(CCCCCCCCC)=O)CCOC(CCCCCCCCC)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 398.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Katsanis E, Sapp LN, Pelayo-Katsanis L, Whitney K, Zeng Y, Kopp LM. Alternative Donor Hematopoietic Cell Transplantation Conditioned With Myeloablative Busulfan, Fludarabine, and Melphalan is Well Tolerated and Effective Against High-risk Myeloid Malignancies. J Pediatr Hematol Oncol. 2016 Nov;38(8):e315-e318. PubMed PMID: 27467368. 2: Boelens JJ, Rocha V, Aldenhoven M, Wynn R, O'Meara A, Michel G, Ionescu I, Parikh S, Prasad VK, Szabolcs P, Escolar M, Gluckman E, Cavazzana-Calvo M, Kurtzberg J; EUROCORD, Inborn error Working Party of EBMT and Duke University. Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. Biol Blood Marrow Transplant. 2009 May;15(5):618-25. doi: 10.1016/j.bbmt.2009.01.020. PubMed PMID: 19361754. 3: Goebel WS, Nelson RP Jr, Brahmi Z, Gowan DJ, Towell PJ, Robertson KA, Haut PR. Serial transplantation resulting in tolerance to an unrelated cord blood graft. Transplantation. 2006 Jun 15;81(11):1596-9. PubMed PMID: 16770250. 4: Neudorf S, Sanders J, Kobrinsky N, Alonzo TA, Buxton AB, Gold S, Barnard DR, Wallace JD, Kalousek D, Lange BJ, Woods WG. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood. 2004 May 15;103(10):3655-61. Epub 2004 Jan 29. PubMed PMID: 14751924. 5: van Pel M, van Breugel DW, Vos W, Ploemacher RE, Boog CJ. Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers. Bone Marrow Transplant. 2003 Jul;32(1):15-22. PubMed PMID: 12815473. 6: de Vries-van der Zwan A, van der Pol MA, de Waal LP, Boog CJ. An alternative conditioning regimen for induction of specific skin graft tolerance across full major histocompatibility complex barriers. Transpl Immunol. 1998 Sep;6(3):147-51. PubMed PMID: 9848220. 7: Copelan EA, Biggs JC, Thompson JM, Crilley P, Szer J, Klein JP, Kapoor N, Avalos BR, Cunningham I, Atkinson K, et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood. 1991 Aug 1;78(3):838-43. PubMed PMID: 1859895.